Updated recommendations to establish normal estradiol reference ranges have been released in a new report from the North American Menopause Society (NAMS).
The report is based on a symposium called “Workshop on Normal Reference Ranges for Estradiol in Postmenopausal Women,” that was held in September 2019, in Chicago, Ill., and featured 28 presentations. The Endocrine Society and the Partnership for the Accurate Testing of Hormones (PATH) were supporters of this symposium.
PATH was established in 2010 to help the clinical, medical, and public health communities improve patient care through more accurate and reliable hormone tests. Improved patient care through the universal use of accurate and reliable hormone tests in healthcare and research is PATH’s chief goal, which is why it was one of the participants in this workshop.
The overarching goal of the symposium was to review existing analytical methodologies for measuring estradiol in postmenopausal women and to assess existing data and study cohorts of postmenopausal women for their suitability to establish normal postmenopause reference ranges.
The anticipated outcome of the workshop was to develop recommendations for establishing normal reference ranges generated with a standardized and certified assay that could be adopted by clinical and research communities.
Aside from the Endocrine Society and PATH, the other organizations that lent support for the symposium include: NAMS, the American Society for Reproductive Medicine, the Centers for Disease Control and Prevention, the International Society for the Study of Women’s Sexual Health, the University of Virginia, Division of Endocrinology and Metabolism, and the International Menopause Society.
Funding companies for the workshop included: Abbott Laboratories, Ansh Labs, ARUP Labs, Endoceutics, Novo Nordisk, Quest Diagnostics, and TherapeuticsMD.